ArticleJournal, genetic engineering & biotechnology2025
Molecular insights into charantin and β-carotene biosynthesis in bitter gourd (Momordica charantia L.): Gene expression dynamics and metabolite profiling.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bitter gourd is recognized for its anticancer and antidiabetic properties, largely attributed to charantin, and is also a rich source of carotenoids, including β-carotene. In this study, considerable variation was observed in both the accumulation and gene expression patterns associated with charantin and β-carotene biosynthesis across diverse genotypes. PVGy-201 exhibited the strongest gene expression profile, with the highest transcript levels for five key genes, including McIDI (∼16,493-fold), McPMK (∼694-fold), and McSE (∼466-fold), which corresponded with the maximum charantin content (38.53 µg/g FW). Similarly, DBGS-2 showed elevated expression of McHMGR1 (∼271-fold) and McMK (∼13-fold), supporting its high charantin accumulation (35.27 µg/g FW). The wild species Momordica balsamina demonstrated strong expression of McHMGR2 and McSE, consistent with charantin content of 29.36 µg/g FW. For β-carotene, DBGS-21-06 recorded peak expression of McPSY (∼17.2-fold), McZDS (∼4.9-fold), and McCHXB (∼2.8-fold), aligning with high carotenoid levels at both edible (18.46 µg/g FW) and ripening (52.31 µg/g FW) stages. Pusa Rasdar showed elevated expression of McZEP (∼6.9-fold) and McPDS (∼10.8-fold), correlating with maximum carotenoid content (19.49 µg/g FW at edible stage and 55.66 µg/g FW at ripening). DBGS-100-0 expressed McLCYE1 (∼2.9-fold) and McLCYE2 (∼3.1-fold), with high carotenoids (15.91 µg/g FW) at the edible stage. Collectively, PVGy-201 and DBGS-2 were identified as promising candidates for charantin enrichment, while DBGS-21-06 and Pusa Rasdar emerged as superior for β-carotene accumulation. These genotype-specific insights provide a molecular framework to support marker-assisted selection, transcriptome-based screening, and metabolic engineering for the development of nutritionally enhanced bitter gourd cultivars with stable metabolite profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.